A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Monday 19 July 2010

Ireland fee hike: your chance to comment

The Irish Patents Office has announced that Ireland's Department of Enterprise, Trade and Innovation is conducting a review of the fees charged for Supplementary Protection Certificates. This seeks to engage with interested parties to seek their views on the proposal to review the current application and renewal fees for Supplementary Protection Certificates. Responses should be received by close of business on Friday 30th July 2010. The rationale for changing fees is as follows:
"Fees for Supplementary Protection Certificates fall somewhat outside the rationale for keeping fees for intellectual property protection low, as the circumstances for granting SPCs are very different to those for granting patents. As a Supplementary Protection Certificate will provide patent protection to a pharmaceutical company up to a maximum of 25 years, a balance must be struck between paying a premium for
continued market monopoly and allowing for entry into the market for generic medicines.
By comparing current fees charged for Supplementary Protection in all Member States of the European Union, Ireland is currently the fourth least expensive country. In cost per head of population (per million) Ireland ranks as the tenth least expensive country of the EU 27, in line with countries with a population of approximately 10 million, namely Belgium, Sweden, Portugal and the Czech Republic. The preliminary fees for consultation as set out would bring Ireland closer in line with countries with similar population size such as Denmark, Finland and Slovakia".
The proposed new fees and European averages are indicated in tabulated form here.

No comments: